

May 11, 2021



# Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18

## Citius to highlight corporate strategy and key pipeline assets Mino-Lok® and NC i-MSK

CRANFORD, N.J., May 11, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.

### Event Details:

Date: May 18, 2021

Time: 10:30am ET

Investors may register for the conference at the [event website](#).

Citius President and Chief Executive Officer Myron Holubiak will focus on the execution of corporate strategy and capital deployment as the Company advances key pipeline assets including Mino-Lok®, a late-stage antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), and NC *i*-MSK, a novel stem cell therapy for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, and the most common cause of respiratory failure and death in COVID-19 patients. Currently, there is no FDA-approved drug therapy available for ARDS.

### About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit [www.citiuspharma.com](http://www.citiuspharma.com).

### Investor Relations for Citius Pharmaceuticals:

Andrew Scott

Vice President, Special Projects

T: 908-967-6677 x105

E: [ascott@citiuspharma.com](mailto:ascott@citiuspharma.com)

Ilanit Allen

T: 908-967-6677 x113

E: [iallen@citiuspharma.com](mailto:iallen@citiuspharma.com)

🔗 View original content: <http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-participate-in-fireside-chat-at-the-gabelli-funds-virtual-microcap-symposium-on-tuesday-may-18-301289094.html>

SOURCE Citius Pharmaceuticals, Inc.